XM does not provide services to residents of the United States of America.

Franco-Nevada Corp reports results for the quarter ended in January - Earnings Summary



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Franco-Nevada Corp reports results for the quarter ended in January - Earnings Summary</title></head><body>
  • Franco-Nevada Corp FNV.TO reported quarterly adjusted earnings of 75 cents​​ per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of 95 cents. The mean expectation of eleven analysts for the quarter was for earnings of 82 cents per share. Wall Street expected results to range from 76 cents to 94 cents per share.

  • Revenue fell 21.2% to $260.10 million from a year ago; analysts expected $258.00 million.

  • Franco-Nevada Corp's reported EPS for the quarter was 41 cents​.

  • The company reported quarterly net income of $79.5 million.

  • Franco-Nevada Corp shares had risen by 4.6% this quarter and gained 11.8% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 7.8% in the last three months.​

  • In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

  • The average consensus recommendation for the gold peer group is also "buy"

Wall Street's median 12-month price target for Franco-Nevada Corp is $139.00

This summary was machine generated from LSEG data August 14 at 12:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Jun. 30 2024

0.82

0.75

Missed

Mar. 31 2024

0.72

0.76

Beat

Dec. 31 2023

0.84

0.90

Beat

Sep. 30 2023

0.89

0.91

Beat

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.